Workflow
*ST天山(300313) - 2023 Q1 - 季度财报
TIANSHAN BIOTIANSHAN BIO(SZ:300313)2023-04-25 16:00

Financial Performance - The company's revenue for Q1 2023 was CNY 23,156,538.66, representing an increase of 85.05% compared to CNY 12,513,598.14 in the same period last year[4] - The net profit attributable to shareholders was a loss of CNY 4,015,972.23, an improvement of 14.63% from a loss of CNY 4,704,224.83 in the previous year[4] - Total operating revenue for Q1 2023 was CNY 23,156,538.66, an increase of 85.4% compared to CNY 12,513,598.14 in the same period last year[28] - The net profit for Q1 2023 was -4,187,542.06 CNY, compared to -4,850,052.66 CNY in Q1 2022, indicating a 13.7% improvement year-over-year[29] - Operating profit for Q1 2023 was -3,577,013.03 CNY, an improvement from -4,253,297.33 CNY in the same period last year, reflecting a 15.9% increase[29] - The company reported a total comprehensive loss of -4,187,542.06 CNY for Q1 2023, compared to a loss of -2,339,570.19 CNY in Q1 2022[30] - Basic and diluted earnings per share for Q1 2023 were both -0.0128 CNY, compared to -0.0150 CNY in Q1 2022[30] Cash Flow and Assets - The net cash flow from operating activities decreased by 60.96% to CNY 5,336,772.76, down from CNY 13,668,439.97 in the same period last year[4] - Current assets totaled CNY 103,617,004.82 as of March 31, 2023, down 11.9% from CNY 117,638,304.71 at the beginning of the year[25] - The company's cash and cash equivalents were CNY 45,331,434.33, a decrease of 4.1% from CNY 47,288,291.92 at the start of the year[24] - Cash and cash equivalents at the end of Q1 2023 were 45,331,434.33 CNY, down from 122,047,971.83 CNY at the end of Q1 2022, representing a 62.9% decline[33] - The total assets at the end of the reporting period were CNY 316,181,952.90, a decrease of 4.81% from CNY 332,145,607.55 at the end of the previous year[4] - Total liabilities decreased to CNY 226,201,543.59 from CNY 237,977,656.18, a reduction of 5.2%[26] Operating Costs and Income - The operating costs rose by 112.71% to CNY 20,922,380.31, compared to CNY 9,835,924.63 in the previous year, reflecting increased sales activity[9] - Total operating costs for Q1 2023 were CNY 27,560,427.12, up 50.1% from CNY 18,369,110.26 in Q1 2022[28] - Operating costs included CNY 20,922,380.31 in cost of goods sold, which rose significantly from CNY 9,835,924.63 in the previous year, reflecting a 112.5% increase[28] - The company reported a significant increase in operating income, primarily due to a rise in live livestock sales volume[9] - The company recorded a 170.30% increase in other operating income, amounting to CNY 118,716.00, mainly from the sale of patent technology[9] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 16,618[11] - As of the report date, the controlling shareholder, Huzhou Haohui, holds 69,211,312 shares, representing 22.11% of the total share capital, with 15,350,000 shares pledged[16] - Chen Dehong holds 37,279,083 shares, accounting for 11.91% of the total share capital, with 36,509,768 shares pledged and all shares frozen[17] Legal and Regulatory Issues - The company was involved in a significant legal case regarding contract fraud, resulting in a judgment that included the return of 37,279,083 shares from Chen Dehong and 78,345,524 shares from other shareholders[20] - The company faced a major loss due to fraudulent activities during the acquisition of Daxiang Advertising, leading to a criminal case against involved parties[20] - The company has been actively pursuing legal actions to recover losses from the fraudulent acquisition, with ongoing litigation against 33 parties involved in the stock transfer dispute[21] - The total transaction price for acquiring 96.21% of Daxiang Advertising was 2,372.6142 million yuan[14] - The company is currently awaiting the outcome of an appeal related to the stock transfer dispute, which has not yet been heard in the second instance[21] Investment and Development - The company's cash inflow from investment activities was CNY 148,172.00, a significant increase from CNY 0.00 in the previous year[10] - Research and development expenses for Q1 2023 were 181,359.78 CNY, a decrease of 16.7% from 217,754.69 CNY in Q1 2022[29] Agricultural Policy Impact - In Q1 2023, the government allocated a total of 20,300 acres for agricultural planting, reflecting a decrease in available planting area due to water resource management policies[19] - The company has been adjusting its operational strategies in response to changes in agricultural policies and legal challenges[19]